Live
- India favours Musk, says no spectrum auction
- Yogi govt to celebrate Tribal Pride Day
- Kartik Aaryan’s ‘Bhool Bhulaiyaa 3’ Surpasses Rs 150 Crore in Just a Week
- BJP MLAs run ‘parallel assembly’ in J&K Assembly lawns
- IND A vs AUS A: KL Rahul fails for second time, India A in trouble at 73/5, with an overall lead of just 11 runs
- Bhujbal denies media reports claiming NCP leaders joined Mahayuti to escape ED
- Indian motorsport youngster Kush Maini moves a step closer to Formula One
- Vijayawada-Srisailam Sea Plane trial run conducted succesfully
- SC refuses to entertain PIL for appointment of ‘Yoga Mitra’ in all schools
- Rahul, Easwaran fail to leave mark as India A reduced to 73/5, after Harris makes 74
Aurobindo Pharma's 3 facilities classified as 'Official Action Indicated'
The US Food and Drug Administration has classified Aurobindo Pharma's three facilities under Official Action Indicated (OAI).
Hyderabad: The US Food and Drug Administration has classified Aurobindo Pharma's three facilities under Official Action Indicated (OAI).
Aurobindo Pharmasaid they have received letters from the FDA, classifying the inspections at its API (Active Pharmaceutical Ingredient) facilities of Unit I and XI and intermediates facility of unit IX in February 2019 as Official Action Indicated (OAI).
According to FDA's definitions, Official Action Indicated means "objectionable conditions were found and regulatory and/or administrative sanctions by FDA are indicated" during inspections.
OAI means an FDA inspection revealed significant objectionable conditions or practices and action must be taken to address the issues.
"The Company has already submitted its initial response to USFDA. The Company is sending further updates on the committed corrective actions,"the drug maker said.
Aurobindo Pharma is confident these OAI classifications would not have an impact on disruption of supplies or revenue from operations of these facilities, it added.
